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Abstract
Background: Heterogeneous nuclear ribonucleoproteins (hnRNPs) of the A/B type (hnRNP A1, A2/B1, A3) are
highly related multifunctional proteins participating in alternative splicing by antagonising other splicing factors,
notably ASF/SF2. The altered expression pattern of hnRNP A2/B1 and/or splicing variant B1 alone in human lung
cancer and their potential to serve as molecular markers for early diagnosis remain issues of intense investigation.
The main objective of the present study was to use paired tumour/non-tumour biopsies from patients with non-
small cell lung cancer (NSCLC) to investigate the expression profiles of hnRNP A1, A2/B1 and A3 in conjunction
with ASF/SF2.
Methods: We combined western blotting of tissue homogenates with immunohistochemical examination of fixed
tissue sections and quantification of mRNA expression levels in tumour versus adjacent normal-looking areas of the
lung in the same patient.
Results: Our study, in addition to clear evidence of mostly uncoupled deregulation of hnRNPs A/B, has revealed
hnRNP A1 to be the most deregulated protein with a high frequency of over-expression (76%), followed by A3
(52%) and A2/B1 (43%). Moreover, direct comparison of protein/mRNA levels showed a lack of correlation in the
case of hnRNP A1 (as well as of ASF/SF2), but not of A2/B1, suggesting that different mechanisms underlie their
deregulation.
Conclusion: Our results provide strong evidence for the up-regulation of hnRNP A/B in NSCLC, and they support
the existence of distinct mechanisms responsible for their deregulated expression.
Background
The biogenesis of mRNA in higher eukaryotes is largely
based on the interplay of a large number of RNA-bind-
ing proteins (RBPs) [1]. Heterogeneous nuclear ribonu-
cleoproteins (hnRNPs) are RBPs that are essential
players in mRNA metabolism, acting as coordinators of
post-transcriptional events (splicing, transport, cellular
localisation, decay and translation of mRNA) by partici-
pating in an extensive network of RNA-RBP interac-
tions. Individual hnRNPs also function in several other
cellular processes, like transcription, DNA repair, telo-
mere biogenesis and cell signalling (reviewed in [2-4]).
As a consequence of their multiple roles in the regula-
tion of gene expression, any malfunctioning, especially
with respect to their deregulated expression in cancer, is
expected to affect the physiological network of RNA-
RBP interactions [5,6].
More than 20 distinct hnRNP proteins have been
identified in human cells, designated hnRNPs A1 to U
in increasing molecular size from 32 to 110 kDa. They
represent a family of abundant nuclear proteins, many
of them sharing common structural motifs, exhibiting
multiple isoforms (products of alternative splicing, as
well as of post-translational modification) and having
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the ability to shuttle between the nuclear and cytoplas-
mic compartments [7,8]. The hnRNP A/B group
includes members of 32-40 kDa having in common two
tandem N-terminal RNA-binding domains of the RRM/
RBD type and a C-terminal auxiliary domain rich in gly-
cine (2xRBD-gly). The most abundant and best charac-
terised are hnRNP A1 and A2/B1, as well as the
recently identified hnRNP A3, all three of which share a
high degree of sequence homology and the presence of
several isoforms originating mainly from alternative spli-
cing (reviewed in [4]). In particular, hnRNP A2/B1 refers
to two isoforms; the major hnRNP A2 and the minor B1
form that results from the inclusion of an extra exon of
12 amino acid residues [9]. Their proportions, both in
protein and mRNA levels, vary in different cells and tis-
sues, with B1 constituting roughly 2-5% of A2 [10,11].
The major nuclear function of hnRNPs is thought to be
in splicing and particularly in alternative splicing. This
is especially the case for hnRNP A1 and A2/B1, which
have been shown to antagonise, in a concentration
dependent manner, protein members of the SR group,
notably ASF/SF2, and to influence the mode of splicing
of mRNA target molecules [12]. Changes in the expres-
sion levels of hnRNP A/B and ASF/SF2 have also been
reported in human colon adenocarcinomas [13] and in a
mouse model of lung carcinogenesis [14].
The overall expression of hnRNP A/B proteins is
known to be tightly regulated during development and
to be tissue- and cell-type specific [11,15]. In rodent and
human lung tissues, high hnRNP A/B levels occur dur-
ing embryonic development that drop dramatically in
the adult lung [16]. Moreover, recent studies that have
simultaneously reduced the protein levels of both
hnRNP A1 and A2 in cultured cells have demonstrated
a role for them in cell proliferation [4], as well as a
strong association of their reduction with cell death in
cancer but not in non-cancer immortalised cells, indi-
cating that cancer cells require these proteins for viabi-
lity [17]. In general, the aberrant expression of hnRNPs
in cancer cells has been documented by a series of stu-
dies [5,18,19] and found to be associated with alterations
in their protein levels (usually over-expression, but also
down-regulation), mRNA abundance, cellular localisa-
tion, isoform types and post-translational modifications
(like patterns of phosphorylation). Of particular impor-
tance are initial findings linking over-expression of
hnRNP A2/B1 with early stages of human lung carcino-
genesis. In an archival study using exfoliated epithelial
cells in sputum, hnRNP A2/B1 over-expression was con-
sidered to be a promising new diagnostic marker able to
accurately predict lung carcinogenesis at least a year
before the appearance of any cytological findings
[19,20]. Correlations between hnRNP A2/B1 over-
expression, microsatellite alterations and loss of
heterogeneity in early stages of malignancy have been
reported [21,22]. Because of the pressing need for early
diagnostic and prognostic biomarkers, these initial
results provided the impetus for a number of subse-
quent studies. Most reports have focused on the expres-
sion patterns of hnRNP A2/B1 and/or the splicing
isoform B1 alone [23-29], whereas one study included
additional hnRNPs (hnRNP A1, C1/C2, K) [30]. hnRNP
A2/B1 over-expression is not unique to lung cancer, as
it has been also recorded in squamous cell carcinomas
of oral and esophageal cancers [25], pancreatic cancer
[31] and in cell lines established from human liver,
colon and stomach cancers [23].
To date, because of contradictory findings, no consen-
sus exists as to the significance of hnRNP A2/B1 over-
expression in early lung carcinogenesis. Moreover, the
exact role of hnRNP A/B proteins in carcinogenesis and
the mechanism of their deregulation remain unclear. To
further elucidate the roles of hnRNP A/B (A1, A2/B1,
A3) in conjunction with the splicing factor ASF/SF2 in
lung cancer, we present here an evaluation of their pro-
tein and mRNA levels in paired tumour/non-tumour
biopsies from NSCLC patients. Our findings should help
to unravel the mode and consequences of their deregu-
lated expression in lung carcinogenesis.
Methods
Tissue samples and patients
Fresh lung biopsies (kept in liquid nitrogen) from a total
of 21 patients who had been operated on for non-small
cell lung cancer (NSCLC), together with adjacent nor-
mal-appearing lung tissue, were randomly selected from
the tissue banks of the Department of Pathology,
Metaxa Cancer Hospital, Piraeus, Greece. The material
was obtained by lung lobe resection and included the
following tumour subtypes: six adenocarcinomas, one
bronchioalveolar carcinoma, three large cell carcinomas,
nine squamous cell carcinomas and two adenosquamous
carcinomas. The ages of the patients ranged from 54 to
78 (average 66) with 18 males and 3 females. Additional
clinico-pathological data refer to the differentiation sta-
tus of the tumour, the state of histiocytes and pleural
invasion, the presence of metastasis in lymph nodes
(LNs) and the tumour-to-node metastasis (TNM) index.
The study was performed under the approval of the
Metaxa Cancer Hospital Bioethics committee of Greece.
Antibodies
The following mouse monoclonal antibodies were
obtained from Santa Cruz Biotec and were used at the
indicated dilutions in western blotting: anti-hnRNP A1,
4B10 (1:1,000); anti-hnRNP A2/B1, DP3B3 (1:1,000); anti-
hnRNP K/J, 3C2 (1:500); anti-hnRNP SF2/ASF, 33652
(1:500). Anti-b-actin mouse monoclonal MAB1501
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antibody was purchased from Chemicon (1:4,000) and rab-
bit polyclonal anti-hnRNP A3 (50949) antibody was from
Abcam Co. (1:2,000). The secondary antibodies were
horseradish peroxidase-conjugated anti-mouse (Sigma Co)
and anti-rabbit (Chemicon-Milipore) IgG.
Tissue homogenisation and western blotting
For every patient, a small portion of the biopsy, taken
from either the cancer area or a remote (> 5 cm) non-
involved lung tissue site, was immediately lysed in a
protein lysis buffer (9.5 M urea, 2% NP-40, 5% b-mer-
captoethanol). Complete homogenisation of the tissue
was done with a rotor-stator homogeniser TissueRuptor
(Qiagen) and TCA precipitation of total protein fol-
lowed. The protein pellet was resuspended in a small
volume (50-100 μl) of SDS sample buffer and roughly
similar amounts of protein (estimated by Coomassie
blue staining of a test gel) of paired tumour and non-
tumour samples were resolved by SDS-PAGE and trans-
ferred to a nitrocellulose membrane. After incubation,
the membrane was incubated in blocking buffer (10 mM
Tris-HCl pH 7.5, 0.1 M MgCl2, 5% low-fat skim milk,
0.5% Τween-20, 0.1% Τriton-X100) with gentle rocking
overnight at 4°C using the appropriate dilution of the
antibody in blocking buffer. The antigen-antibody reac-
tion was visualised following incubation with an HRP-
conjugated secondary antibody and application of the
ECL detection system (Amersham Biosciences, UK).
Semi-quantitative estimation of the test protein was
done by scanning the appropriate band on X-ray film in
a digital scanner with Image Quant software (Molecular
Dynamics, CA) in parallel with that of b-actin run
within the same sample, which was used as an internal
loading control for normalisation. In the relative quanti-
tation of western blots, care was taken to compare
roughly similar detection signals that were within the
linearity range of the X-ray film scanner.
Immunohistochemistry
Pairs of formalin-fixed, paraffin-embedded sections cor-
responding to a resected NSCLC biopsy and its neigh-
bouring normal-looking area were prepared. Fixed
sections from 18 out of the 21 patients that were
included in the western blotting analysis were used for
immunohistochemical detection of hnRNP A1 and A2/
B1 proteins using the above-described anti-hnRNP A1
and anti-hnRNP A2/B1 monoclonal antibodies at 1:300
dilutions. Sections were deparaffinised and incubated
with the antibody overnight at 4°C. Following incubation
with anti-mouse secondary IgG, immunostaining was
developed with diaminobenzidine and counterstained
with hematoxylin. Interpretation of the staining records
and assignment of scoring indexes was done by two
independent pathologists.
Real-time PCR analysis (RT-qPCR)
Total RNA was extracted from a small portion of the
biopsies with the RNeasy Mini Kit (Qiagen) according
to the manufacturer ’s protocol. On-column DNA
digestion (RNase-Free DNase Set, Qiagen) was used to
ensure the absence of DNA from the samples. The
quality of the isolated RNA was tested by its optical
density (260/280 over 1.5) and the presence of 28S and
18S ribosomal RNA resolved by agarose gel electro-
phoresis. The expression of hnRNP A1, A2/B1, B1 and
ASF/SF2 was quantified by real-time PCR (RT-qPCR).
Total RNA (1 μg) was reverse-transcribed using Super-
script II (Invitrogen) reverse transcriptase and oligo-dT
primers according to the manufacturer’s instructions.
Real-time PCR reaction products were synthesised and
quantified by SYBR Green I (iQ SYBR Green Super-
mix, Biorad) on an iQ5 Real-Time PCR Detection Sys-
tem (Biorad) using the ribosomal LP32 gene as an
internal control for normalisation. All assays were per-
formed in triplicate in a 25-μl two-step reaction. The
specificity of the amplified PCR products was assessed
by melting curve analysis and agarose gel electrophor-
esis of a small aliquot of the reaction followed by
staining with ethidium bromide. Relative mRNA levels
of test proteins were determined by the Normalised
Gene Expression method using iQ5 Optical System
Software. The efficiency of the qPCR reaction was
measured in separate assays using serial dilutions of
cDNA obtained from total RNA from the A549 lung
cell line for every gene of interest.
The specific primers were:
hnRNP A1: Forward 5′-CCAGAGAAGATTCTCAAA-
GACC-3′;
Reverse 5′-CTTCAGTGTCTTCTTTAATGCC-3′
hnRNP A2/B1: Forward 5′-AGCTTTGAAACCACA-
GAAGAA-3′;
Reverse 5′-TTGATCTTTTGCTTGCAGGA-3′
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Statistical analysis
The non-parametric Wilcoxon ranked-sum test was
used to statistically analyse the protein and mRNA levels
(from western blotting and RT-qPCR analyses, respec-
tively) of the paired tumour and non-tumour tissues.
Values of p < 0.05 were considered to be significant.
Results
hnRNP protein levels in paired tumour/non-tumour lung
tissue specimens from patients with NSCLC
This study included 21 patients who had been operated
on for non-small cell lung cancer (NSCLC). Table 1 pre-
sents the list of patients along with the available clinico-
pathological data. For every patient, tumour subtype,
differentiation stage (equal numbers of either low or
intermediate stage), extent of histiocyte infiltration, and
presence of pleura invasion is noted. In addition, metas-
tases in lymph nodes (LNs) as well as the tumour-to-
node metastasis (TNM) index with the application of
the new 7th version of TNM classification of the lung
cancer are indicated. The majority of tumours were
associated with a low to medium differentiation stage
and absence of metastasis (M0).
For each of the 21 patients, paired biopsies from the
tumour and from an adjacent normal-appearing area
were provided. Total homogenate was prepared from a
portion of the frozen tissue, followed by protein
resolution by SDS-PAGE. Western blotting was then
used to immunodetect selected members of the hnRNP
protein family. The parallel immunodetection of b-actin,
serving as a cellular protein index, was used to normal-
ise for protein loading. Densitometric scanning of the
identified antigenic bands on the blots was used to
obtain semi-quantitative estimates of the hnRNP protein
levels relative to b-actin within the same sample. We
focused our study on the major hnRNP A/B type pro-
teins that include, in addition to the hnRNP A2/B1 cur-
rently implicated mostly in lung cancer, the hnRNP A1
and A3 protein species. In addition to hnRNP A/B, we
also looked at the relative levels of hnRNP K (a protein
commonly altered in several types of human cancer
[6,18]) using an antibody targeting the pair of hnRNP
K/J proteins. We note that the assessment of hnRNP K
protein level was limited to 16 (out of 21) patients due
to inefficient amount of tissue available.
Α representative western blot for the immunodetec-
tion of b-actin, hnRNP A/B (A1, A2/B1, A3) and K/J
proteins is shown in Figure 1A, which presents 5 out of
the 21 tumour/non-tumour pairs analysed. Western
blotting analysis clearly showed a broad range of altered
hnRNP protein expression levels between the paired
tumour (T) and non-tumour (N) tissues. After normalis-
ing to b-actin, the relative expression level of each of the
hnRNP proteins was calculated. For hnRNP A2/B1, the
Table 1 Clinicopathological characteristics of the 21 NSCLC patients (ID # M1-M27)
A/A SEX AGE TUMOR TYPE DIFFERE-NTIATION HISTIOCYTES PLEURAL INVASION LNs TNM
M1 M 66 Adeno Low FEW NO NO T2aN0M0
M2 M 57 Adeno/Bronch Medium YES NO NO T3N0M0
M7 M 54 SqCC Medium YES NO 1+ T1bN1M0
M9 M 63 SqCC Medium FEW YES * 1+ T1bN1M0
M10 M 57 SqCC Medium/Low FEW YES * NO T2bN0M0
M12 M 65 LCC Low FEW NO YES T3N2M0
M13 M 67 SqCC Medium/Low YES NO NO T1bN0M0
M14 M 69 LCC Low FEW YES * NO T2bN0M0
M15 F 55 Adeno/SqCC Low FEW YES * YES T2aN1M0
M16 F 76 Adeno Medium FEW YES * YES T3N1M0
M17 M 60 Adeno Medium FEW NO NO T3N0M0
M18 M 75 LCC/Adeno Low NO NO 1+ T2aN1M0
M19 F 55 SqCC Medium/Low NO YES pleural nodules/bone invasion 1+ T4N1M1b
M20 M 74 Adeno/SqCC Low NO NO NO T2aN0M0
M21 M 70 Adeno Low NO YES * NO T1bN0M0
M22 M 71 Adeno Low YES NO 1+ T2aN3M0
M23 M 78 SqCC Low YES N/A N/A N/A
M24 M 72 SqCC Medium NO YES * YES T2aN2M0
M25 M 60 Adeno Low N/A N/A N/A N/A
M26 M 62 SqCC Low N/A N/A N/A N/A
M27 M 58 SqCC Low N/A N/A N/A N/A
SqCC: Squamous cell carcinoma; Adeno: Adenocarcinoma; LCC: Large cell carcinoma; Bronch: Bronchioalveolar; LNs: Lymph nodes; TNM: Tumour-to-node
metastasis (7th TNM classification version); M0: absence of metastasis. *pleural invasion with no pleural penetration/no pleural nodules.
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relative amount refers to both the A2 and B1 isoforms
that are recognised by the anti-A2/B1 DP3B3 monoclo-
nal antibody. Although in several cases B1 was clearly
visible on the gel, it was not sufficiently separated from
A2 to allow individual estimates. This was also the case
for the homologous hnRNP K and J protein species that
were considered together. The differences in the hnRNP
expression levels between the paired specimens are
depicted as relative T/N fold-changes for all the patients
included in this study. A relative fold-change of 1 indi-
cates cases with unaltered levels. Cases with clear up-
regulation, cases without an appreciable change and
cases with down-regulation were all observed.
Table 2 presents the cumulative data on the relative T/
N fold-change observed for each hnRNP protein member
with respect to the range of T/N ratio and frequency of
over-expression for all the patients examined. Note that
in the presentation of the T/N range, we have excluded
two patients (M25, M26) because the relative level of
hnRNP A/B in the normal tissue was very low (almost at
a background level) compared to the tumour tissue,
which led to a high T/N fold-change (over 100). To apply
rather stringent criteria on protein over-expression that
was based on semi-quantitative estimates, we deliberately
raised the baseline of the relative T/N fold-change from 1
(non-altered levels) to 2. As seen, a broad range of rela-
tive T/N fold-change was observed for each protein
tested, with hnRNP A1 having the broadest range, fol-
lowed by hnRNP A3. Similarly, the recorded frequency of
over-expression was higher for hnRNP A1 (76%), fol-
lowed by A3 (52%), A2/B1 (43%) and K/J (38%). The
most statistically significant values of over-expression
Figure 1 A representative western blotting analysis of lung tissue homogenates. Total protein obtained from paired tumour (T) and non-
tumour (N) tissues of NSCLC patients was resolved by SDS-PAGE (10% gel) followed by transfer to nitrocellulose membrane and western
blotting. (A) Immunodetection within the same material of the hnRNP proteins (hnRNP A1, A2/B1, A3 and K/J) and (B) of the ASF/SF2 splicing
factor was done by incubating the membrane with the appropriate antibodies. The parallel detection of b-actin served as an internal loading
control for estimating relative protein expression levels.
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were obtained for A1, followed by A3. Less significant
were the estimates of A2/B1, and even less were those for
K/J. Cases with a high degree of over-expression (T/N >
10) were also included, and these were found to be higher
for hnRNP A1 (43%), followed by A3, A2/B1 and K/J (see
Figure 2). The above findings taken together clearly indi-
cate that hnRNP A1 is the most highly and frequently
deregulated protein in NSCLC.
Based on the histogram shown in Figure 2, a direct
comparison was made individually for every patient
included in this study of the three homologous hnRNP
A/B type proteins (hnRNP A1, A2/B1 and A3) with
respect to both their frequency and the degree of their
altered expression. Overall, the cases with up-regulated
hnRNP A/B levels were more common than those with
down-regulated hnRNP A/B levels. We note, however,
that in roughly 20% of the patients with up-regulated
levels, there was down-regulation in at least one of the
hnRNP A/B proteins. This comparison provides clear
evidence that deregulation among the hnRNP A/B pro-
teins is largely uncoupled, as exemplified by their differ-
ent degree of over-expression and (mainly) by the cases
with opposite (up versus down) deregulation in the
same patient. With respect to the relative T/N fold-
changes in hnRNP K/J, there was mostly parallel expres-
sion with hnRNP A1 (data not shown).
As stated in the Background section [12-14], the
antagonistic behaviour between hnRNP A/B proteins
and the splicing factor ASF/SF2 in the splicing of target
mRNA molecules and the existence of a strong link
between deregulated splicing events and cancer are
important issues to consider. We therefore extended the
western blotting analysis of hnRNPs to include the
immunodetection of ASF/SF2 protein in the same sam-
ple. This analysis included only 16 (out of 21) patients
for the reasons stated in the case of hnRNP K. In Figure
1B, a representative blot of five biopsies is shown for
ASF/SF2 in parallel with b-actin as the loading control.
Similarly to the hnRNPs, we compared the relative
expression levels of ASF/SF2 in the tumour (T) and
non-tumour (N) specimens and obtained estimates of
the relative T/N fold-change in the same patient. As
presented in Table 2, compared to the hnRNP proteins,
the frequency of ASF/SF2 over-expression was low (31%
with T/N > 2), and moreover, it was correlated with a
very poor significance value (p = 0.42). In the total num-
ber of biopsies (n = 16) included in this analysis, and in
direct comparison with hnRNP A1 as the protein with
the highest frequency and degree of altered expression
in the tumours, a high frequency (75%) of concurrent
deregulation of ASF/SF2 and hnRNP A1 was apparent,
representing mainly over-expression of both proteins
Table 2 Protein-level estimates: Western blotting results
Fold-change T/N (Protein-level)
Protein Range of T/N Frequency of over-expression T/N > 2 (no. of cases) Significance (p-value)
hnRNP A1 0.4 - 30.0 76% (16/21) 0.0006
hnRNP A2/B1 0.4 - 9.0 43% (9/21) 0.0199
hnRNP A3 0.6 - 28.0 52% (11/21) 0.0025
hnRNP K/J 0.2 - 7.0 38% (6/16) 0.0319
ASF-SF2 0.1 - 19.0 31% (5/16) 0.4228
Figure 2 Comparison of the relative expression levels of the hnRNP A/B proteins in paired tumour and normal biopsies. A histogram
presenting the relative fold change of the tumour-to-normal (T/N) value of paired biopsies for hnRNP A1, A2/B1 and A3 protein levels
individually for every patient (M1-M27) included in this analysis.
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(data not shown). However, there were fewer cases with
ASF/SF2-relative T/N fold-changes over 10 (12%; 2/16)
than with hnRNP A1 over 10 (43%; 9/16).
Evaluation of the expression pattern of hnRNP A1 and
A2/B1 by immunohistochemistry
To investigate the extent to which the western blotting
results were consistent with immunohistochemistry
results, the anti-hnRNP A1 and A2/B1 antibodies were
also used for in situ visualisation of the respective anti-
genic proteins on formalin-fixed paraffin-embedded tis-
sue sections prepared from the same group of patients.
Specific cellular staining, both nuclear and cytoplasmic,
was recorded and compared between the tumour and
the surrounding normal-appearing area of the biopsy
from each patient. The degree of immunostaining was
scored 0 for no staining, 1 for low staining, 2 for inter-
mediate staining and 3 for high staining. In line with
other relevant immunohistochemical studies [29,30], we
also noted a variable number of cells with no expression
at all (0) next to stained cells within the same area.
There were also some cases with extensive heterogeneity
in the staining distribution of epithelial cells within the
non-tumour area (a score of 1, 2 or even 3), possibly
related to the clonality of pre-cancerous cells [32].
A representative picture is shown in Figure 3 of the
hnRNP A1 or A2/B1 antibody staining of selected non-
involved (normal; panels a and b) and cancer tissues of
an NSCLC type adenocarcinoma (panels c and d) and
an NSCLC type squamous cell carcinoma (panels e and
f). In the great majority of cases (see the selected case in
Figure 3c and 3e), hnRNP A1 was recorded in cells of
the tumour site with an intermediate to high range of
nuclear staining (score 2 to 3) and practically unde-
tected cytoplasmic staining; in addition, there were
some cells with no expression at all. This contrasted
with the picture of the normal site showing low level or
total lack of nuclear staining (score 1 or 0) (see Figure
3a). However, a few exceptional biopsies presenting
broader heterogeneity (score 0, 1, 2 and low numbers of
3) should be noted. Overall, good agreement with the
western blotting results was found. In particular, all
paired biopsies with a relative T/N fold-change over 10
(43%) were scored with a high (3) nuclear staining in
the tumour site. Unlike that of hnRNP A1, the immu-
nostaining pattern of hnRNP A2/B1 was not as distinct,
mainly due to cells in the non-tumour site of the biopsy
having a broad spectrum of nuclear staining (several
with a score of 2 and 3) when contrasted with the corre-
sponding low levels of hnRNP A1 (Figure 3b and 3a,
respectively). In the tumour site, all biopsies had a high
(3) score for nuclear hnRNP A2/B1 and (with the excep-
tion of one) low cytoplasmic hnRNP A2/B1 staining (see
examples in Figure 3d and 3f). After taking into
consideration this apparently high baseline level of
hnRNP A2/B1 in the normal-appearing site of the
tumour, there was good correspondence with the rela-
tive expression levels of the protein; 43% over-expres-
sion as estimated by western blotting. This was
highlighted by the high frequency (over 50%) of tumour
samples without up-regulated levels of hnRNP A2/B1
(relative T/N fold-change less than 2), unlike A1 (Figure
2). Lastly, our immunohistochemical study did not pro-
vide data that correlated with either the sub-type (squa-
mous vs. adenocarcinoma) or the differentiation (low vs.
intermediate) stage of the tumour.
Direct comparison of protein and mRNA levels of hnRNP
A/B and ASF/SF2 in paired tumour/non-tumour tissues
A major goal of our study was to investigate cancer-
related changes in the protein and mRNA levels of both
hnRNPs and ASF/SF2 in the same biopsy. To this end,
in parallel with protein isolation, a small portion of the
biopsy was used to obtain total RNA. Paired tumour/
non-tumour biopsies were used to obtain total RNA,
and an equal amount was subsequently reverse tran-
scribed and subjected to real-time PCR amplification
(RT-qPCR) using primers specific for hnRNP A1, A2/
B1, the B1 isoform alone and ASF/SF2. As with the pro-
tein estimation, the mRNA level was reported as the
relative fold-change between the paired tumour and
non-tumour (T/N) sites for each patient. For mRNA
estimates, we used a lower baseline setting (T/N fold-
change 1.5, instead of 2 in the case of the protein esti-
mates) taking into account the use of the quantitative
RT-qPCR method.
Table 3 presents the cumulative data on the range and
frequency of mRNA over-expression, based on estimates
provided by a number of 15 to 20 patients (as indicated)
for whom sufficient amount of extracted RNA was avail-
able. With the baseline of T/N fold-change at 1.5, the
frequency of mRNA up-regulation was 15% for hnRNP
A1, 40% for A2 and B1 together and 37% for B1 alone.
A frequency of 20% was estimated in the case of ASF/
SF2 mRNA. Most importantly, a statistically significant
value of mRNA over-expression was seen only for A2/
B1 mRNA, whereas the least significant value was for
A1.
From the comparison of the range and frequency of
protein over-expression (Table 2) and the mRNA-level
estimates shown in Table 3, it became obvious that in
the case of hnRNP A1 there was a lack of correspon-
dence between its protein and mRNA levels. This is also
clearly shown in the histogram of Figure 4 (panel
hnRNP A1), which directly compares protein and
mRNA levels for every patient included in this analysis.
The high frequency of hnRNP A1 over-expression (76%)
was not in line with the corresponding 15% value of its
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mRNA levels. In fact, in 33% of the cases, there was
opposing regulation, with up-regulated levels of the pro-
tein and concurrent down-regulated mRNA. A mis-
match in the range of altered expression was also
apparent because in almost one-third of cases there was
a much greater degree of protein over-expression
compared to mRNA. In the case of hnRNP A2/B1, this
mismatch was not apparent (Figure 4, panel hnRNP A2/
B1)), as the same frequency of over-expression (40%)
was estimated for both protein and mRNA levels. There
were also cases of opposing regulation of A2/B1 pro-
tein/mRNA levels at a frequency of 14% (compared to
Figure 3 Estimates of hnRNP A1 and A2/B1 expression levels by immunohistochemistry. A representative picture showing staining with
anti-hnRNP A1 or anti-hnRNP A2/B1 monoclonal antibodies of fixed lung sections of either non-involved (normal; a and b) or lung cancer
tissues of the adenocarcinoma (c and d) or squamous cell carcinoma (e and f) subtype. Original magnification: all x200. A representative tissue
area corresponding to panels a - f was selected and is shown in a magnified view as an insert picture.
Table 3 mRNA-level estimates: Real-time PCR results
Fold-change T/N (mRNA level)
mRNA Range of T/N Frequency of over-expression T/N > 1.5 (no. of cases) Significance (p-value)
hnRNP A1 0.2 - 5.0 15% (3/20) 0.6407
hnRNP A2/B1 0.4 - 30.0 40% (8/20) 0.0196
hnRNP B1 0.4 - 14.4 37% (7/19) 0.1650
ASF-SF2 0.4 - 2.0 20% (3/15) 0.1182
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33% for A1). In clear contrast to hnRNP A1, there were
several cases (4/21) that presented a higher fold-change
in the mRNA level compared to the protein. With
respect to the B1 isoform alone, the change in its
mRNA level was within the range (about 40%) recorded
for the sum of A2 and B1 (see Tables 2 and 3). How-
ever, due to the lack of direct estimates of hnRNP B1
protein levels, a comparison between its protein and
mRNA levels could not be made.
The RT-qPCR analysis of the ASF/SF2 splicing factor
showed a 20% frequency of mRNA up-regulation, an
estimate that was close to the 15% of hnRNP A1. The
data presented in the histogram of Figure 4 (panel ASF/
SF2), where the direct comparison of ASF/SF2 protein
and mRNA level is depicted, reveal a high occurrence
(over 50%) of opposing changes. With the exception of
one biopsy, this involved over-expression of the protein
and concurrent down-regulation of the mRNA, a situa-
tion resembling that of hnRNP A1. In addition, a strict
comparison of the mRNA levels of ASF/SF2 and hnRNP
A1 revealed that 10 out of 15 biopsies exhibited parallel
changes (either up- or down regulation). Thus, similarly
to the changes at the protein level, the cancer-related
alterations of ASF/SF2 mRNA were in line with those of
hnRNP A1.
Discussion
The main advantage of the present study was the use of
paired tumour/non-tumour biopsies from NSCLC
patients for estimating both protein and corresponding
Figure 4 Direct comparison of hnRNP A/B and ASF/SF2 protein and mRNA levels in paired tumour and normal biopsies. Histograms
presenting the relative fold change in the tumour to normal (T/N) value of paired biopsies for hnRNP A1 (upper panel), A2/B1 (middle panel)
and ASF/SF2 (lower panel) protein and mRNA levels in the indicated patients.
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mRNA levels of the hnRNP protein species under inves-
tigation. The study was based on the combined applica-
tion of western blotting and immunohistochemistry for
semi-quantitative estimates of protein levels and RT-
qPCR analysis for the quantification of steady-state
mRNA levels.
A series of studies have reported the altered expres-
sion of hnRNPs, mainly of hnRNP A2/B1, in lung
carcinogenesis. Most of the studies used immunohisto-
chemistry on resected NSCLC tissues or immunocyto-
chemistry on lung cancer cell lines [25-29,33,34]. In
several cases, western blotting, northern blotting and/or
RT-PCR were also included [20,22-24,30,35]. So far, our
study is unique with respect to the exclusive application
of paired tumour/non-tumour lung biopsies and direct
comparison of protein and mRNA levels of particular
hnRNP protein species. It is believed that biopsies are
better suited for the study of lung carcinogenesis than
cultured human cell lines (either established or primary
cultures), which exhibit altered growth rates. In general,
it has been difficult to have proper normal control cell
lines because immortalised non-cancerous cells have
hnRNP levels comparable to those of cancerous cells.
This needs to be taken into consideration because
expression levels of hnRNPs are tightly linked to cell
proliferation [4].
Initial and subsequent reports in the literature have
pointed to the altered expression pattern of hnRNP A2/
B1 protein and mRNA in lung cancer. This was taken as
a feature of cellular neoplastic transformation preceding
morphological differentiation, and it could be useful for
the early detection of lung cancer [20,33,34,36]. A high
frequency of increased expression of hnRNP A2/B1, as
well as of other hnRNPs (A1, C1/C2, K), was found by
immunostaining human SCLC and NSCLC cell lines as
well as NSCLC biopsies [30]. In the cell lines, the average
levels of hnRNP A2/B1 and A1 mRNA were higher in
SCLC than in NSCLC, as was the ratio of A2 to B1
mRNA (average value 7.2 and 6.3 in SCLC and NSCLC,
respectively) [30]. However, the initial encouraging find-
ings on hnRNP A2/B1 over-expression have come into
question with respect to its usefulness as a diagnostic
biomarker for early lung cancer. This is because other
studies claimed that instead, the B1 splicing isoform was
more significantly elevated both at the protein and
mRNA level in lung cancer. The application of polyclonal
antibodies exclusively recognising the hnRNP B1 variant
resulted in strong nuclear staining, mainly of squamous
cell carcinoma, but not of the normal lung epithelial cells
adjacent to tumours [24,27]. In other reports, some posi-
tive staining of normal cells (albeit of lower intensity
than with cancer cells) has been detected with two
monoclonal anti-B1 antibodies [23,28,35]. In an exclusive
immunohistochemical study using archived tissue
sections of resected lung cancers in parallel with control
non-cancer tissues from benign lung disease unrelated to
cancer, B1 expression was also seen (at a frequency of
25%) in benign bronchial epithelial cells and inflamma-
tory cells of the control group [28]. Nonetheless, hnRNP
B1 expression is seen from the early stages of malignant
transformation (in occult cancer, bronchial dysplasia and
sputum) and is currently considered to be a more specific
and sensitive biomarker than hnRNP A2/B1 for the early
detection of lung cancer [24,25,27].
In the framework of the above discussion, we believe
that our work brought out a number of important
issues. A first observation concerns the cancer-related
changes at the protein level within the highly related
group of hnRNP A/B. Apart from the deregulation of
hnRNP A2/B1 and B1 alone, there have been few
reports on other hnRNP proteins. Our work focused on
all three major hnRNP A/B-type proteins, namely
hnRNP A2/B1, A1 and A3, whereas an additional
hnRNP protein (hnRNP K) was included in some appli-
cations. The semi-quantitative estimates that were based
on western blotting revealed the prominence of hnRNP
A1 with respect to its higher degree of deregulation
(range and frequency of over-expression) in NSCLC. By
applying a threshold based on adjacent normal-appear-
ing area separately in every patient, the tumour-to-nor-
mal ratio was found to be most significantly changed in
the case of hnRNP A1 (76%), followed by hnRNP A3
(52%), A2/B1 (43%) and K/J (38%). (Table 2). The high
frequency of hnRNP A1 over-expression in NSCLC seen
in our study was a clear finding that confirmed and
extended previous observations based on immunohisto-
chemistry alone [30]. Over-expression of hnRNP A1 was
not exclusive to NSCLC, as it was also seen in SCLC
biopsies by immunohistochemistry (Valavanis C., perso-
nal communication). In addition, it did not appear to be
restricted to lung cancer, as we had similar findings in
breast cancer biopsies by immunoblotting (our unpub-
lished observation). Increased expression of hnRNP A1
has also been reported in colon [37] and several other
cancer types [17]. Our finding of hnRNP A3 over-
expression is novel and requires further investigation for
its potential application in lung carcinogenesis.
The alterations in the relative amounts of hnRNP A1
and A2/B1 we observed by western blotting were in
overall agreement with the semi-quantitative estimates
from the immunohistochemical analysis. Moreover, a
clear distinction in the immunostaining pattern of
hnRNP A1 and A2/B1 in the normal lung tissue was
apparent. This had to do with a high threshold in the
intensity of nuclear staining for hnRNP A2/B1 in the
normal-appearing area of the lung (scoring index 1, 2
and few 3) in contrast to the very low staining index for
A1 (Figure 3). This finding on A2/B1 staining intensity
Boukakis et al. BMC Cancer 2010, 10:434
http://www.biomedcentral.com/1471-2407/10/434
Page 10 of 13
agrees well with previous observations. hnRNP A2/B1
protein and mRNA were expressed at almost equal
levels in cancerous and non-cancerous tissues [16], and
increased protein expression (around 40%) has been
noted in both normal and abnormal bronchial epithe-
lium of the lung in chronic smokers [33] and in non-
neoplastic respiratory epithelium [20].
Moreover, immunohistochemical analysis showed
mainly nuclear localisation of hnRNP A1 and A2/B1 in
the cells within the cancer area, similar to the staining of
the neighbouring normal-appearing cells. However, con-
tradictory observations exist in the literature with respect
to hnRNP cellular localisation in cancer cells. Both
nuclear and cytoplasmic staining of hnRNP A2/B1 have
been reported in [33,34]. Nuclear staining of hnRNP A2/
B1 has also been observed in the case of mouse lung ade-
nocarcinomas [38], and nuclear staining of the hnRNP
B1 isoform has been reported by others [35]. However,
the study of Pino et al. [30] on NSCLC tissues claimed
primarily cytoplasmic localisation of hnRNP A2/B1, con-
trasting with the nuclear staining of hnRNP A1 and C1/
C2, whereas hnRNP K was both nuclear and cytoplasmic.
The cytoplasmic accumulation of hnRNP A2/B1 in asso-
ciation with tumour progression has been shown [21].
These discrepancies might be due to the different antibo-
dies and fixation protocols applied.
The main objective of our study was the direct com-
parison of hnRNP A1 and A2/B1 at the protein and
mRNA levels within the same patient. The high fre-
quency (76%) of hnRNP A1 protein over-expression in
cancer was not accompanied by similar changes in its
steady-state mRNA level (15% up-regulation). In con-
trast to hnRNP A1, the same overall frequency (about
40%) of over-expression at the protein and mRNA levels
was estimated for hnRNP A2/B1. Our study estimated
the mRNA level of the B1 splicing variant alone, but it
did not assess its protein level in parallel due to the
unavailability in this framework of specific antibodies.
However, the western blots using the anti-hnRNP A2/
B1 antibody showed overall changes of B1 proportional
to A2. Moreover, the frequency and range of B1 mRNA
elevation in cancer were parallel to those of A2/B1
mRNA, although of lower significance (Table 3). Thus,
our findings did not appear to agree with the report of
Sueoka et al. [24] regarding elevated levels of hnRNP B1
mRNA compared to A2/B1 mRNA in lung cancer.
We also wish to comment that the lung cancer tissues
used in our study were of a rather advanced cancer
stage (low or intermediate differentiation). Nonetheless,
the adjacent normal-appearing lung tissue 5 cm away
from the boundary of the tumour area selected as a
standard showed no signs of hyperplasia or metaplasia.
Without doubt, a better control would have been the
use of lung cancer biopsies from non-cancer patients,
which would be expected to provide very low back-
ground levels of hnRNP A/B [16], but which were not
available for the present study.
Our results provide strong evidence that supports the
existence of distinct mechanisms responsible for hnRNP
A/B deregulation in lung cancer, as suggested by a pre-
vious study [30]. This was manifested at the protein
level by the frequent cases of opposing alterations (up-
vs. down-regulation) in at least one of the hnRNP A/B
members within the same biopsy. Most importantly, this
apparent non-concurrent deregulation of hnRNP A/B
protein levels was also reflected at the mRNA level.
Based on the parallel quantification of the respective
tumour-to-normal mRNA ratio, there was an absence of
strict correlation between protein and mRNA levels in
hnRNP A1. The high frequency (76%) of protein over-
expression in cancer was not accompanied by similar
changes in its steady-state mRNA level (15% up-regula-
tion). We wish to note in this context that an apparently
poor correlation between protein and mRNA levels in
eukaryotic systems has been reported because quite
often protein over-expression is not accompanied by
similar changes at the mRNA level [39,40].
As noted in the Results, we detected in cancer tissue an
alteration parallel to that of hnRNP A1 in both the pro-
tein and mRNA levels of ASF/SF2, a factor with a known
antagonistic role to A1 in alternative splicing [12]. In a
mouse model, although the relative amounts of both pro-
teins changed during lung carcinogenesis, hnRNP A1
increased to a much higher extent in tumours (six-fold
increase of hnRNP A1 relative to ASF/SF2) [14]. This
also appears to be the case in human lung cancer, as in
our study an increase of hnRNP A1 relative to ASF/SF2
was apparent in 80% of the cases (the majority with over
a three-fold increase). These data add support to the exis-
tence of cancer-related alterations in the relative amounts
of the splicing factors ASF/SF2 and hnRNP A1 that need
to be further verified with respect to their significance in
lung carcinogenesis.
Contradictory results on the usefulness of hnRNP A2/
B1 for predicting early lung cancer still exist. Along these
lines is a recent study by Zech et al. [29] on the diagnos-
tic and prognostic value of hnRNP A2/B1 or B1 alone in
lung cancer. By applying large-scale immunohistochemis-
try to frozen (not paraffin-embedded) sections of paired
tumour/non-tumour biopsies from NSCLC patients, the
frequency of A2/B1 over-expression in cancer was found
to be particularly low; 10% compared to 91% of B1 in the
cancer cells. In results contrasting with the report of Wu
et al., [26] a prognostic value of B1 was not seen, whereas
A2/B1 over-expression was associated with a negative
prognosis [29]. As for the other discrepancies mentioned
above, the existence of such contradictory results is
thought to be related to the different antibodies and
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tissue fixation methods applied. In our study, we
observed a higher frequency of hnRNP A1 over-expres-
sion than hnRNP A2/B1 over-expression, as seen both by
western blotting and immunohistochemistry. The possi-
bility nonetheless remains that hnRNP A1 alterations
occur at a later stage of malignant transformation of the
lung compared to A2/B1 or B1.
The present study has not addressed the question of
the clinical usefulness of hnRNP A1 over-expression in
the pathological diagnosis of lung cancer. However, the
low score index for the staining of hnRNP A1 in the
neighbouring non-involved lung tissue, when contrasted
with the higher score of hnRNP A2/B1 in the same area
(see Figure 3), highlighted the need for evaluating hnRNP
A1 as a new molecular index that can be combined with
the hnRNP B1 variant as well as other promising biomar-
kers (like telomerase expression and K-Ras mutations;
discussed in [25]) for accurately predicting early lung car-
cinogenesis. Additionally, the observation of hnRNP A1
over-expression might provide a potential new target for
disease management and intervention.
Currently, the molecular basis of deregulated expres-
sion of hnRNP proteins in lung cancer is not known.
The involvement of signalling molecules that control
hnRNP protein activity might be anticipated, as has
been shown in the case of ASF/SF2 over-expression in
breast and colon cancer [13]. A link between hnRNP A/
B overexpression and carcinogenesis is provided by the
finding on their requirement for cancer cell growth [17]
and on the impairment of DNA repair upon hnRNP B1
over-expression [41]. Our study provided some initial
indications related to the underlying mechanism(s) of
altered hnRNP A/B expression in NSCLC. The differ-
ences seen in the pattern of deregulation between the
two highly homologous proteins hnRNP A1 and A2/B1
are in line with the anticipated high complexity of the
molecular events underlying malignant transformation
in humans, with the intervention of mechanisms operat-
ing in a synergistic or an antagonistic way at several
steps of the mRNA metabolism of a particular gene.
One possible mechanism to explain hnRNP A1 protein
over-expression in the absence of parallel changes in the
corresponding mRNA level (shown in the present study)
could involve translational repression of hnRNP A1
mRNA in non-tunourous normal cells that is lost in
cancer cells and leads to protein accumulation. Such a
mechanism may involve specific microRNA species that
could target hnRNP A1 mRNA, in line with recent
reports implicating the role of a number of microRNAs
in lung carcinogenesis [42]. Whether such a mechanism
exists in the case of hnRNP A1 mRNA remains to be
shown. Nonetheless, caution should be taken when
interpreting results based on gene expression analysis at
the mRNA level alone without considering changes in
the cell’s proteome. Relevant future studies aiming to
define the specific mRNA subsets associated with lung
carcinogenesis that are most affected by hnRNP A/B
over-expression would be of particular interest.
Conclusion
In this study, we demonstrate altered expression of the
splicing factors hnRNP A/B and ASF/SF2 in cancer
patients with non-small cell lung cancer. The applica-
tion of semi-quantitative protein estimates and real time
RT-PCR analysis on paired cancer/non-cancer lung
biopsies from 21 patients allowed for direct comparisons
of the protein and corresponding mRNA expression
profiles to be made. We provide evidence for mostly
uncoupled deregulation among members of the hnRNP
A/B group (A1, A2/B1 and A3). hnRNP A1 was the pro-
tein species with the highest degree and frequency of
altered expression, but it also showed a clear lack of
correlation between its protein and mRNA expression
levels. These findings add to our current understanding
of hnRNP A/B deregulation in lung cancer, and further
studies evaluating their potential application as diagnos-
tic/prognostic biological markers are warranted.
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